GM25313
iPSC from Fibroblast
Description:
MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD
DYSTROPHIN; DMD
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
Muscular Dystrophies |
| Protocols |
Protocol PDF |
|
Biopsy Source
|
Skin
|
|
Cell Type
|
Stem cell
|
|
Cell Subtype
|
Induced pluripotent stem cell
|
|
Transformant
|
Reprogrammed (Episomal)
|
|
Sample Source
|
iPSC from Fibroblast
|
|
Race
|
White
|
|
Country of Origin
|
USA
|
|
Family Member
|
1
|
|
Family History
|
N
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Clinical summary/Case history
|
|
ISCN
|
46,XY[25].arr[hg19] Xp21.1(31,959,887-32,118,084)x0
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| Passage Frozen |
20 |
| |
| Induced Pluripotent Stem Cell |
The parental cell line was recovered, reprogrammed to an induced pluripotent stem cell line, and expanded. The expanded line was evaluated for viability surface antigen expression and alkaline phosphatase activity. Pluripotency was assessed via embryoid body (EB) formation. Steady-state mRNA expression patterns of undifferentiated iPSC and EBs were determined via real-time PCR. Characterization data are included in the Certificate of Analysis. |
| |
| Gene |
DMD |
| Chromosomal Location |
Xp21.2 |
| Allelic Variant 1 |
; DUCHENNE MUSCULAR DYSTROPHY |
| Identified Mutation |
EX45DEL |
| Remarks |
iPSC derived from GM05112 Fibroblast by episomal reprogramming; Clinically affected with Duchenne muscular dystrophy; diagnosed with neuromuscular disease at age one; progressive proximal weakness; calf hypertrophy; normal IQ; at age six there was toe walking, tight heelcords, limited range of motion in ankles and hip extension, good trunk strength, hamstring tightness, lumbar lordosis; by age nine there was a modified Gower's maneuver, gluteal gait, absent deep tendon reflexes, intact antigravity muscles in upper extremities, weakness of lower extremities, quads 2/5, knee extensor 2/5, knee flexors 3/5, weakness to ankle extensor more so than flexion, diminishment of pulmonary function; became wheelchair bound between ages 9 and 11; at age 11 there was progressive weakness in lower extremities, contractures at knees, hips and ankles, bicep and tricep strength grade IV+ bilaterally; ability to raise arms above head without difficulty; affected brother is GM05114/15; son of GM05116/17 (mother) and GM05118/19 (father); elevated CPK at age 1; muscle biopsy at age 10 revealed characteristic picture of a myopathy of the Duchenne muscular dystrophy type; donor subject has a deletion of exon 45 in the dystrophin gene as determined by multiplex PCR; same donor as GM05113 (lymphocyte). Researchers purchasing hiPSCs from the NIGMS Repository are responsible for any limited use label licenses (LULLs) applicable to the cell line purchased. The applicable LULL to this line is iPS Academia Japan, Inc.. |
| Fabre P, Molina T, Orfi Z, Dumont NA, Assessment of Muscle Function Following hiPSC-Derived Myoblast Transplantation in Dystrophic Mice Current protocols2:e356 2022 |
| PubMed ID: 35085428 |
| |
| Zhang Y, Li Y, Hu Q, Xi Y, Xing Z, Zhang Z, Huang L, Wu J, Liang K, Nguyen TK, Egranov SD, Sun C, Zhao Z, Hawke DH, Li J, Sun D, Kim JJ, Zhang P, Cheng J, Farida A, Hung MC, Han L, Darabi R, Lin C, Yang L, The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin Nature cell biology22:1332-1345 2020 |
| PubMed ID: 33106653 |
| |
| Caputo L, Granados A, Lenzi J, Rosa A, Ait-Si-Ali S, Puri PL, Albini S, Acute conversion of patient-derived Duchenne muscular dystrophy iPSC into myotubes reveals constitutive and inducible over-activation of TGFß-dependent pro-fibrotic signaling Skeletal muscle10:13 2019 |
| PubMed ID: 32359374 |
| |
| Kim E, Wu F, Wu X, Choo HJ, Generation of craniofacial myogenic progenitor cells from human induced pluripotent stem cells for skeletal muscle tissue regeneration Biomaterials248:119995 2019 |
| PubMed ID: 32283390 |
| |
| Tang Z, Berlin DS, Toji L, Toruner GA, Beiswanger C, Kulkarni S, Martin CL, Emanuel BS, Christman M, Gerry NP, A dynamic database of microarray-characterized cell lines with various cytogenetic and genomic backgrounds G3 (Bethesda, Md)3:1143-9 2013 |
| PubMed ID: 23665875 |
| Gene Cards |
DMD |
| Gene Ontology |
GO:0003779 actin binding |
|
GO:0005200 structural constituent of cytoskeleton |
|
GO:0005509 calcium ion binding |
|
GO:0005856 cytoskeleton |
|
GO:0006936 muscle contraction |
|
GO:0007016 cytoskeletal anchoring |
|
GO:0007517 muscle development |
|
GO:0008270 zinc ion binding |
|
GO:0016010 dystrophin-associated glycoprotein complex |
| NCBI Gene |
Gene ID:1756 |
| NCBI GTR |
300377 DYSTROPHIN; DMD |
|
310200 MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD |
| OMIM |
300377 DYSTROPHIN; DMD |
|
310200 MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD |
| Omim Description |
APO-DYSTROPHIN 1, INCLUDED |
| |
BMDDYSTROPHIN, INCLUDED; DMD, INCLUDED |
| |
CARDIOMYOPATHY, X-LINKED DILATED, INCLUDED; XLCM, INCLUDED |
| |
MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC PROGRESSIVE, DUCHENNE AND BECKERTYPES; DMD |
| Passage Frozen |
20 |
| Split Ratio |
1:4 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Ham's F12 Medium/Dulbecco Modified Eagles Medium, 1:1 mixture with 2mM L-glutamine or equivalent |
| Serum |
20% Knock-out Serum Replacement Not inactivated |
| Substrate |
Gelatin + Feeder Layer |
| Supplement |
Basic Fibroblast Growth Factor 10ng/ml |
|
|